Fondaparinux: A cornerstone drug in acute coronary syndromes

Table 4 Fondaparinux with unfractionated heparin during revascularization in acute coronary syndromes 8: Primary outcomes at 48 h

Primary outcomes at 48 h	Standard dose UFH (n = 1002)	Low dose UFH (n = 1024)	Odds ratio	95%CI	P value
Peri-PCI major, minor, bleeds and vascular access complications	5.80%	4.70%	0.80	0.54-1.19	0.27
Components
Major bleeds	1.20%	1.40%	1.14	0.53-2.49	0.73
Minor bleeds	1.70%	0.70%	0.40	0.16-0.97	0.04
Major vascular access site complications	4.30%	3.20%	0.74	0.47-1.18	0.21

UFH: Unfractionated heparin; CI: Confidence interval; PCI: Percutaneous coronary intervention.